Belt and braces approach may prevent deep vein thromboses

October 07, 2008

Combining short periods of leg compression with medications such as heparin is more effective at preventing blood clots in high-risk patients than using either preventative measure alone. A team of Cochrane Researchers believe that this 'belt and braces' approach can significantly decrease a patient's risk of deep vein thrombosis (DVT).

DVT can be fatal if the clot breaks free and travels to the lungs (pulmonary embolism). They can also cause severe leg swelling and ulcers - a condition known as post-thrombotic syndrome.

While DVTs have grabbed media attention when they occur in people who have sat in cramped conditions (e.g. economy class syndrome), they are much more common in patients undergoing surgery, hospitalised with severe illnesses or with leg fractures. Most occur in the legs. Healthcare providers often recommend anticoagulant medications such as heparin, which thin the blood, as preventative measures for patients at high risk of DVT. Alternatively, using a pump to inflate an airtight bag around the leg can also prevent blood "pooling" and reduce the risk.

By analysing data from eleven trials involving 7,431 patients, Cochrane Researchers found that a combined approach to prevention reduced the risk of DVT from 4 in 100 to less than 1 in 100 when compared to anticoagulants alone. When compared to compression alone, the risk of DVT was reduced from 4 in 100 to 1 in 100.

"Our results support guidelines that already recommend the combined use of medication and leg compression to prevent deep vein blood clots," says lead researcher, Stavros Kakkos of the Henry Ford Hospital in Detroit, Michigan.

There is, however, still some uncertainty as to whether the combined approach reduces a patient's risk of a life-threatening pulmonary embolism caused by a clot travelling to the lungs.

"If these clots get into the lungs they can be fatal. We urgently need more studies to find out whether combined preventative approaches are also useful in preventing pulmonary embolism," says Kakkos.
-end-


Wiley

Related Heparin Articles from Brightsurf:

UC San Diego researchers move closer to producing heparin in the lab
In a new study published in PNAS, UC San Diego researchers moved one step closer to the ability to make heparin in cultured cells.

Rivaroxaban superior to heparin in preventing blood clots after common orthopedic surgeries
The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Hitting HIT: Heparin therapy
Heparin is widely used as an anticoagulant, but evokes in some patients a potentially life-threatening condition called HIT.

URI chemistry professor develops contaminant detection technique for heparin
In 2008, a contaminant eluded the quality safeguards in the pharmaceutical industry and infiltrated a large portion of the supply of the popular blood thinner heparin, sickening hundreds and killing about 100 in the US.

Synthetic version of popular anticoagulant poised for clinical trials
A synthetic version of low molecular weight heparin is poised for clinical trials and development as a drug for patients with clotting disorders, and those undergoing procedures such as kidney dialysis, heart bypass surgery, stent implantation, and knee and hip replacement.

Heparin stimulates food intake and body weight gain in mice
Research shows that heparin, which is well known for its role as an anticoagulant, can also promote food intake and body weight increase in animal models.

Apixaban lowers stroke risk in AF patients undergoing cardioversion (EMANATE)
Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented today in a Hot Line LBCT Session at ESC Congress.

No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study today in JACC: Cardiovascular Interventions.

Smart patch releases blood thinners as needed
An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occurrence of dangerous blood clots.

Two differing medications used during heart procedure are both safe and effective, study finds
Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention, a non-surgical procedure to open blood vessels narrowed by plaque buildup, according to a new study.

Read More: Heparin News and Heparin Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.